of Participants (Studies) Follow-up Quality of the Evidence (GRADE) Relative Effect Anticipated absolute effects Risk with LMWH and VKA Risk difference with Rivaroxaban (95% CI) All-cause mortality Moderatec because of imprecision (from 6 fewer to 6 more) Recurrent VTE 8,281 Moderatec because of imprecision (from 7 fewer to 5 more) Major bleeding 8,246 High (from 3 fewer to 11 fewer) The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). EINSTEIN-DVT Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis; EINSTEIN-PE Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism. See Table 1 legend for expansion of other abbreviations and GRADE Working Group grades of evidence. a Included patients had acute, symptomatic, objectively veri ed proximal DVT of the legs or PE (unprovoked, 73%; cancer, 5%; previous VTE, 19%). b Rivaroxaban 20 mg daily for 6 or 12 mo after initial long-term therapy. c CI includes values suggesting no effect and values suggesting either bene t or harm. d Pooled analysis of Bauersachs et al21 (EINSTEIN-DVT) and Buller et al26 (EINSTEIN-PE) performed by Prins et al.183 Bibliography: Prins et al183 TABLE 4 ] Summary of Findings: Apixaban vs LMWH and VKA for Acute and Long-Term Treatment of VTEa,b Outcomes No. 